Clinical Trial Update: A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant chemotherapy in nasopharyngeal cancer patients with residual Epstein-Barr virus DNA after radiotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Nasopharyngeal Cancer | Phase 3 | Status: COMPLETED